$243 Million is the total value of Virtus ETF Advisers LLC's 399 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ZLAB | New | ZAI LAB LTDadr | $520,000 | – | 2,937 | +100.0% | 0.21% | – |
| CERE | New | CEREVEL THERAPEUTICS HLDNG I | $422,000 | – | 16,484 | +100.0% | 0.17% | – |
| BRW | New | SABA CAPITAL INCOME & OPRNTshares | $393,000 | – | 83,478 | +100.0% | 0.16% | – |
| SAVA | New | CASSAVA SCIENCES INC | $252,000 | – | 2,951 | +100.0% | 0.10% | – |
| SESN | New | SESEN BIO INC | $243,000 | – | 52,632 | +100.0% | 0.10% | – |
| PSTX | New | POSEIDA THERAPEUTICS INC | $243,000 | – | 24,287 | +100.0% | 0.10% | – |
| ACIU | New | AC IMMUNE SA | $239,000 | – | 30,187 | +100.0% | 0.10% | – |
| EPIX | New | ESSA PHARMA INC | $235,000 | – | 8,233 | +100.0% | 0.10% | – |
| BCAB | New | BIOATLA INC | $237,000 | – | 5,603 | +100.0% | 0.10% | – |
| RXDX | New | PROMETHEUS BIOSCIENCES INC | $234,000 | – | 9,519 | +100.0% | 0.10% | – |
| BCYC | New | BICYCLE THERAPEUTICS PLCsponsored ads | $228,000 | – | 7,509 | +100.0% | 0.09% | – |
| STTK | New | SHATTUCK LABS INC | $228,000 | – | 7,854 | +100.0% | 0.09% | – |
| CRIS | New | CURIS INC | $224,000 | – | 27,718 | +100.0% | 0.09% | – |
| PMVP | New | PMV PHARMACEUTICALS INC | $224,000 | – | 6,556 | +100.0% | 0.09% | – |
| CLVS | New | CLOVIS ONCOLOGY INC | $222,000 | – | 38,303 | +100.0% | 0.09% | – |
| CMPS | New | COMPASS PATHWAYS PLCsponsored ads | $218,000 | – | 5,724 | +100.0% | 0.09% | – |
| IMCR | New | IMMUNOCORE HLDGS PLCads | $220,000 | – | 5,634 | +100.0% | 0.09% | – |
| ANVS | New | ANNOVIS BIO INC | $215,000 | – | 2,518 | +100.0% | 0.09% | – |
| IDYA | New | IDEAYA BIOSCIENCES INC | $214,000 | – | 10,177 | +100.0% | 0.09% | – |
| LXRX | New | LEXICON PHARMACEUTICALS INC | $214,000 | – | 46,699 | +100.0% | 0.09% | – |
| KYMR | New | KYMERA THERAPEUTICS INC | $214,000 | – | 4,421 | +100.0% | 0.09% | – |
| BOLT | New | BOLT BIOTHERAPEUTICS INC | $212,000 | – | 13,706 | +100.0% | 0.09% | – |
| CMRX | New | CHIMERIX INC | $212,000 | – | 26,472 | +100.0% | 0.09% | – |
| MRUS | New | MERUS N V | $208,000 | – | 9,876 | +100.0% | 0.09% | – |
| OLMA | New | OLEMA PHARMACEUTICALS INC | $209,000 | – | 7,479 | +100.0% | 0.09% | – |
| SBTX | New | SILVERBACK THERAPEUTICS INC | $207,000 | – | 6,701 | +100.0% | 0.08% | – |
| HYD | New | VANECK VECTORS ETF TRhigh yld mun etf | $207,000 | – | 3,250 | +100.0% | 0.08% | – |
| ALDX | New | ALDEYRA THERAPEUTICS INC | $206,000 | – | 18,201 | +100.0% | 0.08% | – |
| KRON | New | KRONOS BIO INC | $205,000 | – | 8,554 | +100.0% | 0.08% | – |
| PASG | New | PASSAGE BIO INC | $205,000 | – | 15,459 | +100.0% | 0.08% | – |
| NRIX | New | NURIX THERAPEUTICS INC | $201,000 | – | 7,570 | +100.0% | 0.08% | – |
| AVIR | New | ATEA PHARMACEUTICALS INC | $202,000 | – | 9,395 | +100.0% | 0.08% | – |
| CCCC | New | C4 THERAPEUTICS INC | $201,000 | – | 5,312 | +100.0% | 0.08% | – |
| GRTS | New | GRITSTONE BIO INC | $200,000 | – | 21,930 | +100.0% | 0.08% | – |
| ABCL | New | ABCELLERA BIOLOGICS INC | $200,000 | – | 9,111 | +100.0% | 0.08% | – |
| GRCL | New | GRACELL BIOTECHNOLOGIES INCsponsored ads | $200,000 | – | 15,363 | +100.0% | 0.08% | – |
| PRAX | New | PRAXIS PRECISION MEDICINES I | $197,000 | – | 10,801 | +100.0% | 0.08% | – |
| MGTA | New | MAGENTA THERAPEUTICS INC | $192,000 | – | 19,673 | +100.0% | 0.08% | – |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $189,000 | – | 7,893 | +100.0% | 0.08% | – |
| PRLD | New | PRELUDE THERAPEUTICS INC | $190,000 | – | 6,622 | +100.0% | 0.08% | – |
| CGEM | New | CULLINAN ONCOLOGY INC | $187,000 | – | 7,281 | +100.0% | 0.08% | – |
| KDNY | New | CHINOOK THERAPEUTICS INC | $188,000 | – | 13,299 | +100.0% | 0.08% | – |
| EVLO | New | EVELO BIOSCIENCES INC | $188,000 | – | 13,690 | +100.0% | 0.08% | – |
| VOR | New | VOR BIOPHARMA INC | $187,000 | – | 10,026 | +100.0% | 0.08% | – |
| FBRX | New | FORTE BIOSCIENCES INC | $185,000 | – | 5,512 | +100.0% | 0.08% | – |
| FDMT | New | 4D MOLECULAR THERAPEUTICS IN | $184,000 | – | 7,642 | +100.0% | 0.08% | – |
| TSHA | New | TAYSHA GENE THERAPIES INC | $184,000 | – | 8,697 | +100.0% | 0.08% | – |
| NUVB | New | NUVATION BIO INC | $183,000 | – | 19,604 | +100.0% | 0.08% | – |
| TARS | New | TARSUS PHARMACEUTICALS INC | $183,000 | – | 6,319 | +100.0% | 0.08% | – |
| CDAK | New | CODIAK BIOSCIENCES INC | $162,000 | – | 8,755 | +100.0% | 0.07% | – |
| BKLN | New | INVESCO EXCH TRADED FD TR IIsr ln etf | $150,000 | – | 6,778 | +100.0% | 0.06% | – |
| PRTK | New | PARATEK PHARMACEUTICALS INC | $146,000 | – | 21,447 | +100.0% | 0.06% | – |
| ALGS | New | ALIGOS THERAPEUTICS INC | $146,000 | – | 7,167 | +100.0% | 0.06% | – |
| GMTX | New | GEMINI THERAPEUTICS INC | $127,000 | – | 19,673 | +100.0% | 0.05% | – |
| ATHA | New | ATHIRA PHARMA INC | $118,000 | – | 11,530 | +100.0% | 0.05% | – |
| TEVA | New | TEVA PHARMACEUTICAL INDS LTDsponsored ads | $3,000 | – | 353 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC | 31 | Q3 2023 | 1.7% |
| REGENERON PHARMACEUTICALS | 31 | Q3 2023 | 1.8% |
| INCYTE CORP | 31 | Q3 2023 | 2.1% |
| ENANTA PHARMACEUTICALS INC | 31 | Q3 2023 | 2.2% |
| EXELIXIS INC | 31 | Q3 2023 | 1.8% |
| VANDA PHARMACEUTICALS INC | 31 | Q3 2023 | 1.7% |
| IRONWOOD PHARMACEUTICALS INC | 31 | Q3 2023 | 2.0% |
| LIGAND PHARMACEUTICALS INC | 31 | Q3 2023 | 1.5% |
| GILEAD SCIENCES INC | 31 | Q3 2023 | 1.6% |
| HALOZYME THERAPEUTICS INC | 31 | Q3 2023 | 1.7% |
View Virtus ETF Advisers LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-15 |
| 13F-HR | 2023-11-07 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View Virtus ETF Advisers LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.